Tagged with AstraZeneca

UK Last year the UK-based pharma industry warned against the country’s waning competitiveness, condemning the government’s statutory scheme designed to control drug prices. UK-headquartered AstraZeneca joined the battle cry, claiming it would be choosing Ireland over Britain, a decision the company has now more than revised with a GBP 650 million…

China The biggest pharma industry stories coming out of China, including the impact of the US Biosecure act on Chinese giants WuXi AppTec and WuXi Bio; Novartis’ acquisition of SanReno Therapeutics; the first orphan drug designation for a Chinese herbal medicine-based therapy, and AstraZeneca’s new production line in Taizhou.   Eisai…

China Two leading regional pharma executives, from Eli Lilly and Boehringer Ingelheim respectively have recently moved to head up China operations; perhaps a sign that despite recent geopolitical tensions, multinational biopharma is again/still betting on the country. With innovation-friendly healthcare reforms in place, as well as measures to encourage foreign investment,…

Turkey A roundup of the biggest pharma and healthcare stories from Turkey including the investigation of 19 pharma companies by the country’s competition watchdog; Gen Pharma Caucasus Manufacturing’s new plant in Azerbaijan; drug shortages resulting from a newly adopted currency-indexed medication supply system, and the surge in upper respiratory tract infections…

USA The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) approved no less than 55 new drugs in 2023, a number surpassing that of 2022 by almost 50 percent. While 28 rare disease treatments and five novel gene therapies got the green light, the agency also…

Portugal Sérgio Alves describes the personal and professional factors that drove his return to Portugal, where he draws on enriching experiences gained from working in various European markets. He also discusses how AstraZeneca’s COVID-19 vaccine served as a jumping-off point for more wide-ranging discussions with governmental stakeholders, and the affiliate’s positive…

United Kingdom The recent FDA decision to investigate the serious risk of patients developing new cancers after treatment with CAR-T therapies may have created some bad press around cell and gene therapies, but AstraZeneca has continued to consolidate its ambitions in the area with the acquisition of China-based cell therapy biotech, Gracell…

China The latest pharma industry and healthcare news coming out of China including AstraZeneca’s acquisition of Gracell Biotechnologies; the alarming drop in enrolment in China’s state health insurance system; Huadong Medicine/Impact Therapeutics cancer drug deal; new Changchun GeneScience Pharmaceutical R&D centre in Shanghai, and MGI Tech’s bet on Australia.   AstraZeneca,…

United Kingdom AstraZeneca has made a bold move by offering its in-house digital clinical trial expertise to clinical research organisations (CROs) and other pharmaceutical companies via the launch of healthtech business Evinova. AstraZeneca’s apparent willingness to share expertise with its competitors has raised some eyebrows, but the British firm is steadfast in…

Hong Kong While much of PharmaBoardroom’s recent report on Hong Kong and the Greater Bay Area looks at how Hong Kong is attempting to position itself as a development and financing hub for health tech start-ups, just as important are the multinational pharma companies with commercial operations in the city, providing Hong…

Morocco A highly experienced stalwart of the North African pharma industry, Amine Sekhri today heads up AstraZeneca’s operations in Morocco. In his latest PharmaBoardroom conversation, Sekhri shares his delight at the positive healthcare transformations taking place across Morocco and Africa, gives his insight into the market access landscape for AstraZeneca’s most…

LatAm A roundup of some of the latest news from Latin American pharma, including Acino’s acquisition of M8 Pharmaceuticals; AstraZeneca’s growth in Mexico; Neuraxpharm’s expansion into Brazil and Mexico, and Columbia’s decision to issue a compulsory license for GSK/ViiV’s HIV treatment.   Colombia set to issue a compulsory license for an…